It’s a bit of a secret/surprise, but actually we TOTALLY GIVE IT AWAY IN THIS GIF, actually. Warning: What happens in the photobooth does not stay in the photobooth. (*Disclaimer: Bill Nye does not actually work with us, but he’s always in our hearts.) 9. Big Data is so hot right now…plus who doesn’t get excited by data? Especially when you don’t have to process it? That is literally the name of one of the talks. 6. Infamous Mendeley SocialĪin’t no party like a Mendeley party cause a Mendeley party don’t stop. To make you wish we were back in the sun. We’re not only hearing from our API team, but some of the third-party developers who have successfully used our API and created the apps you love. We just released Mendeley API Version 1, and we’re ridiculously excited about it. We’re not a bunch of cats behind the wheels, we actually have plans! And we want to share them with you. Unable to make it to London? We’ll be streaming live with an interactive Google Hangout! Register here. You’re a rockstar in the world of research, we’re rockstars in the world of research (if we do say so ourselves), so it makes sense we have it in a rockin’ location. In true clickbait-style (you’re here, aren’t you?) here are the top 15 things we’re looking forward to at Mendeley Open Day.

You can also follow along on Twitter with the hashtag #MDOD14, or on our brand-new Instagram account. Register for reminders and your chance to * win* your own Mendeley Open Day prize pack. Unable to attend in person? Tune in on 1 October at 10am BST to check out our interactive livestream and we’ll keep you in the loop. We have a packed schedule for our 1 October event, held in London. The Open Day is to connect our user community, including our Advisors and Librarians, together with the Mendeley team, with a smattering of special guest speakers and hilarious entertainment for good measure. Emerging health care delivery models that target integrated care may be crucial in providing appropriate treatment for elderly T2DM patients with complex conditions.The days have flown by and now we are less than a week away from the Mendeley Open Day. Elderly-specific patient complexities were not associated with time to treatment intensification, emphasizing a positive effect of the integrated health care delivery model. Less than half of elderly patients with inadequately controlled T2DM received treatment intensification. However, after adjusting for demographic, insurance, clinical characteristics, and health care utilization, we found that only polypharmacy was associated with time to treatment intensification (adjusted hazard ratio, 1.10 95% CI = 1.04-1.15 P = 0.001). The median time to treatment intensification did not significantly differ by the elderly-specific patient complexities that included cognitive impairment and depression. Elderly patients with urinary incontinence had a longer median time to treatment intensification (18.6 months) versus those without urinary incontinence (14.6 months). Median time to treatment intensification was shorter for elderly patients with T2DM with polypharmacy (16.5 months) and falls and fall risk (12.7 months) versus those without polypharmacy (20.4 months) and no fall risk (18.6 months). Overall, 48.7% of patients received intensified treatment during follow-up, with median time to intensification 18.5 months (95% CI = 17.7-19.3). Based on the consensus statement for diabetes care in elderly patients published by the American Diabetes Association and the American Geriatric Society, elderly-specific patient complexities were defined as the presence or absence of 5 geriatric syndromes: cognitive impairment depression falls and fall risk polypharmacy and urinary incontinence. In this observational, retrospective cohort study, elderly (aged ≥ 65 years) Medicare beneficiaries (n = 16,653) with inadequately controlled T2DM (hemoglobin A1c ≥ 8.0% despite 2 OADs) were included. To examine the association between time to treatment intensification of T2DM and elderly-specific patient complexities. Few studies have been done to understand treatment intensification among elderly patients failing multiple oral antidiabetic drugs (OADs). Among elderly patients, the management of type 2 diabetes mellitus (T2DM) is complicated by population heterogeneity and elderly-specific complexities.

Mendeley docear at same time